GlassScriptPhysician profile
Silvana Pannain
NPI 1558423004
$225,853.55
in general payments reported to CMS, 2019-2025
9 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $14K · 2022: $26K · 2023: $11K · 2024: $65K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $142K · Travel and Lodging: $11K · Consulting Fee: $4,875 · Food and Beverage: $3,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $141,575.89 |
| Travel and Lodging | $10,702.96 |
| Consulting Fee | $4,875.00 |
| Food and Beverage | $3,796.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $104,116.89 | 2024-2025 | Zepbound, Taltz, Mounjaro |
| Novo Nordisk INC | $103,183.31 | 2019-2025 | Wegovy, Ozempic |
| Madrigal Pharmaceuticals | $14,741.32 | 2025 | Rezdiffra |
| Eli Lilly and Company | $3,600.00 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $91.02 | 2020 | |
| Vivus LLC | $71.17 | 2022 | |
| Covidien LP | $37.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvana Pannain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.